A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

841

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: PP6M
DRUG: PP3M 350 mg eq.
DRUG: PP3M 525 mg eq.
DRUG: PP1M
OTHER: Placebo

Sponsor

Janssen Research & Development, LLC